10x Genomics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Saxonov Serge (Chief Executive Officer) sold 25,000 shares of 10x Genomics, Inc. (TXG) at an average of $81.22 ($78.23–$82.36, $2.03M total) across 5 trades on 2026-09-22 under a Rule 10b5-1 trading plan.
10x Genomics Inc. (TXG) stock rose 12.23% on September 24, 2026, driven by investor optimism over AI partnerships and a legal win. The company's stock has increased over 35% in under a month, reaching $84.91. TXG reported $151M in quarterly revenue with a 70% gross margin but remains unprofitable. Analysts have mixed views, with targets around $70, while traders focus on momentum and future growth potential.
ARK ETFs sold 16,422 Alphabet (GOOGL) shares for $5.8M, bought 359,612 Rocket Lab (RKLB) shares for $25.1M. Also reduced Twist Bioscience (TWST) and 10X Genomics (TXG) positions, while increasing stakes in Scribe Therapeutics (SCTX), Veracyte (VCYT), and Beam Therapeutics (BEAM).
Over the past 7 days, AlphAI's AI scored 8 news stories mentioning TXG (10x Genomics, Inc.). Coverage has skewed bearish: 2 bullish, 2 neutral, and 4 bearish.
Recent TXG coverage spans market movers, insider activity and financial news.
In the last 30 days, TXG insiders filed 16 SEC Form 4 transactions — no purchases and 16 sales ($6.7M). The most active reporter was SULIMAN SHEHNAAZ with 5 filings. 81% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sale signals potential short‑term pressure on the stock.
The legal victory and AI deal enhance TXG's competitive moat and growth narrative, likely supporting further upside in the near term.
Limited price effect for 10X Genomics.
Divestiture may slightly depress TXG price.
Divestiture could pressure TXG lower in the short term.
AlphAI scores every news story that mentions TXG with an AI model for sentiment and relevance, and aggregates insider trades from 10x Genomics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Saxonov Serge (Chief Executive Officer) sold 25,000 shares of 10x Genomics, Inc. (TXG) at an average of $81.22 ($78.23–$82.36, $2.03M total) across 5 trades on 2026-09-22 under a Rule 10b5-1 trading plan.
1 min read10x Genomics Inc. (TXG) stock rose 12.23% on September 24, 2026, driven by investor optimism over AI partnerships and a legal win. The company's stock has increased over 35% in under a month, reaching $84.91. TXG reported $151M in quarterly revenue with a 70% gross margin but remains unprofitable. Analysts have mixed views, with targets around $70, while traders focus on momentum and future growth potential.
3 min readARK ETFs sold 16,422 Alphabet (GOOGL) shares for $5.8M, bought 359,612 Rocket Lab (RKLB) shares for $25.1M. Also reduced Twist Bioscience (TWST) and 10X Genomics (TXG) positions, while increasing stakes in Scribe Therapeutics (SCTX), Veracyte (VCYT), and Beam Therapeutics (BEAM).
2 min readARK Genomic Revolution ETF (ARKG) managed by Cathie Wood bought shares of Ionis Pharmaceuticals (IONS), Veracyte (VCYT), Beam Therapeutics (BEAM), and Scribe Therapeutics (SCTX), while selling 10x Genomics (TXG). Other ETFs like GNOM, PBE, FBT, and XBI also hold these biotech companies, offering varied exposure to genomics and biotechnology sectors.
2 min readARK Invest increased stakes in Ionis Pharmaceuticals (IONS), Veracyte (VCYT), Scribe Therapeutics (SCTX), and Beam Therapeutics (BEAM), while reducing exposure to 10x Genomics (TXG). The ETF bought shares worth millions in each biotech firm, with IONS, SCTX, and BEAM seeing pre-market gains, while VCYT declined. ARK also invested $37 million in Meta Platforms (META) across three ETFs, following a surge in Meta's shares.
2 min readArk Invest, led by Cathie Wood, bought $24.7M of CoreWeave and $7.25M of Meta Platforms, while selling $40M of its Bitcoin ETF and reducing holdings in AMD, Alphabet, Shopify, and Palantir. The firm also adjusted healthcare and aerospace positions, signaling a shift toward AI infrastructure.
2 min readCathie Wood's Ark Invest sold crypto-linked positions including ARK 21Shares Bitcoin ETF (ARKB), Coinbase (COIN), and Circle Internet Group (CRCL) on Monday, then bought CoreWeave (CRWV) shares on Thursday after the company announced new contracts and a funding plan. CRWV stock fell 4% this week. Other notable trades included AeroVironment (AVAV) and Meta Platforms (META).
3 min readARK Invest, led by Cathie Wood, sold shares in multiple crypto-linked holdings, including ARKB, COIN, CRCL, and BMNR. The firm trimmed over 1.5% of its Bitcoin ETF (ARKB) positions. Bitcoin's price fell below $77,000, and retail sentiment remained bearish. Other tech stocks like AMZN, AMD, and SHOP were also reduced.
2 min readTaich Adam (Chief Financial Officer) sold 46,388 shares of 10x Genomics, Inc. (TXG) at an average of $64.57 ($63.68–$65.26, $3.00M total) across 3 trades on 2026-09-09 under a Rule 10b5-1 trading plan.
2 min readLunit, a South Korea-based AI cancer diagnostics company, will integrate its Lunit SCOPE IO platform with 10x Genomics' oncology biomarker discovery workflow. The collaboration aims to enhance tumor analysis by combining pathology images with spatial molecular data, supporting clinical research on antibody-drug conjugates and immunotherapy. Lunit's AI analyzes tissue features, complementing 10x's molecular profiling. According to the companies, this partnership may lead to future diagnostic appl
1 min read
